Vincent Milano

Vincent Milano was appointed to the Board in July 2021. Mr. Milano has over 25 years of rare disease leadership experience. He most recently served as chief executive officer of Idera Pharmaceuticals, Inc., and previously served as chairman, president, and chief executive officer of ViroPharma, which successfully developed and launched Cinryze for the treatment of HAE in the United States and Europe, prior to its acquisition by Shire in 2014. Prior to joining ViroPharma in 1996, he served as a senior manager at KPMG LLP, an independent registered public accounting firm. Mr. Milano currently serves on the boards of directors of Idera Pharmaceuticals, Aclaris Therapeutics, and VenatoRx Pharmaceuticals, and is the chairman of the board for Life Science Cares Philadelphia. He received his Bachelor of Science degree in accounting from Rider College.